FOXO4-DRI Dosage Chart & Schedule Guide.

No. As of 2026 there is not one completed or registered human trial; a ClinicalTrials.gov search for FOXO4 returns zero interventional studies. Everything on this page traces back to mouse experiments and cell culture. Cleara Biotech, the Dutch spin-out founded on this work, remains preclinical and has publicly shifted its focus toward the FOXO4–p53 interaction generally rather than this specific peptide. Anyone injecting FOXO4-DRI is running a single-person experiment and should frame it that way, both to themselves and to their doctor.

Because it is a senolytic, not a signalling peptide. BPC-157 or ipamorelin nudge a pathway that resets the moment you stop, so daily dosing makes sense for them. FOXO4-DRI deletes cells. Once the accessible senescent population is gone, further injections have no substrate to act on; in the mouse chemotherapy model, adding FOXO4-DRI on top of genetic senescent-cell clearance produced no additional benefit at all. Three doses across five days, then months off, is the entire published design.

Unknown, and this is the biggest quiet assumption in every FOXO4-DRI dosing chart, including this one. Baar 2017 dosed intravenously; the Leydig-cell and pulmonary-fibrosis follow-ups dosed intraperitoneally. No published study has given it subcutaneously or measured what fraction reaches circulation that way. FOXO4-DRI is a roughly 5.4 kDa, strongly cationic TAT-fusion peptide, and cationic peptides tend to bind extracellular matrix at the injection site, so subQ delivery could plausibly be substantially lower than IV. Treat subQ unit charts as convention rather than pharmacology.

Applying the standard FDA body-surface-area conversion (divide the mouse dose by 12.3) gives about 0.41 mg/kg, or roughly 28 mg per injection for a 70 kg adult (around 85 mg for a full three-dose course, which is eight or nine 10 mg vials). Real-world protocols run 1 to 3.3 mg per injection, roughly a tenth of that. So the honest position is not that community doses are dangerous overkill but the opposite: nobody has demonstrated that the doses people actually use do anything at all. Cost, not evidence, set the community dose.

There is no evidence-based answer. The published work never ran repeat courses, and human senescent-cell re-accumulation rates have never been measured. Common practice is one to three courses a year with 3 to 6 months between them, but that figure appears only on peptide sites and has no study behind it. The relevant caution from the paper's own discussion is that FOXO4 has a normal role in DNA-damage repair and Foxo4-knockout mice handle acute damage badly, which is why the authors explicitly ruled out permanent FOXO4 inhibition. Erring toward longer gaps is the safer mistake.

Add 2 mL of bacteriostatic water slowly down the inside wall of a 10 mg vial (never squirt it onto the powder and never shake it), then swirl gently until clear. That gives 5 mg/mL, so 1 mg is 20 units on a U-100 syringe, 2.5 mg is 50 units and 3.3 mg is 66 units. Keep unopened lyophilised vials in the freezer; once mixed, refrigerate at 2–8 °C and use within about four weeks. Since a full course is only three injections across five days, one mixed vial covers it comfortably and long-term storage of reconstituted peptide never becomes an issue.

There is no human data on combining senolytics, and one relevant detail sits in Baar's own paper: they tested dasatinib and quercetin against senescent IMR90 fibroblasts, found no selectivity for senescent cells in their hands, and dropped the combination for that reason. Stacking two agents that both push cells toward apoptosis multiplies the unknowns without any evidence of additive benefit. If you are going to run an unvalidated compound, run one at a time so that anything that happens can actually be attributed.

Most likely not much, and that is the expected outcome rather than a sign of a bad batch. In animals nothing measurable moved until roughly week three: running-wheel activity at day 18 to 21, kidney markers and fur density at day 30. Anything noticed inside 48 hours is more plausibly the mild inflammatory malaise reported anecdotally after doses than a therapeutic effect. If a vendor or protocol promises noticeable results within days, that is a marketing claim with nothing behind it.